611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Cancer
Resources
Basic InformationLatest News
Can a Computer Program Help Docs Spot Breast Cancer?Trials Show COVID Vaccines Well Worth It for Cancer PatientsCancer in Hispanics: Good News and BadRadiation Therapy for Breast Cancer May Have Long-Term Risk for the HeartCommon Form of Liver Cancer on the Rise in Rural AmericaNew Drug Combo Boosts Survival Against Aggressive Form of Breast CancerPeople With MS Have Worse Survival If Colon Cancer StrikesHaving Even a Cousin or Grandparent With Colon Cancer Raises Your Risk: StudyBlood Cancer Patients Could Benefit From COVID Booster Shot: StudyYour State's Laws Might Save Your Life If Breast Cancer Strikes9/11 First Responders Face Higher Cancer Risk 20 Years LaterChild Cancers Are Rare, But Here Are Signs to Look ForIn Cancer Patients, COVID Vaccine Immunity at 6 Months Is Similar to General PopulationWhich Cancer Patients Need a COVID Booster Shot Most?AI May Not Be Ready to Accurately Read MammogramsToo Many Antibiotics Might Raise Colon Cancer RiskPandemic Brought Big Drop in Breast Cancer Screening in Older, Low-Income WomenFewer American Adults Are Getting Malignant Brain TumorsDon't Forget to Apply Sunscreen Before & After Water FunExercise Could Help Fight 'Chemo Brain' in Breast Cancer PatientsSpotting the Signs of Deadly Melanoma Skin CancersVitamin D Might Help Prevent Early-Onset Colon CancerFar Too Few People of Color in U.S. Pancreatic Cancer TrialsDeath of Spouse Could Raise Men's Odds for Prostate CancerCancer Patients Avoiding Pot, Even as Rules on Use RelaxOne Key Question Can Help Spot Skin CancerImmune-Based Therapy May Help Some Battling Advanced Colon CancersIncomplete Polyp Removal During Colonoscopy Can Bring Cancer DangerFatigue Before Treatment Starts Might Affect Cancer SurvivalNew Drug Might Be Non-Surgical Option for Common Skin CancersHow Did the Pandemic Affect Cancer Clinical Trials?Many Black Men Missed Out on Prostate Cancer Care During PandemicMixed Progress Against Cancers in Teens, Young AdultsBogus Info on Cancer Common Online, and It Can HarmScreening Often Misses Endometrial Cancer in Black WomenLong Distance to Care Can Mean Worse Outcomes for Young Cancer PatientsAlcohol Tied to 740,000 Cancer Cases Worldwide in 2020Cancer Survivors Fared Better Financially After ObamacarePandemic Delays in Screening Mean More Breast Cancer Deaths Ahead: StudyObese Men May Have Better Survival With Advanced Prostate CancerMost Cancer Screenings Make Big Rebound After Pandemic DeclineAdding MRI to Screening Can Cut Prostate Cancer Overdiagnosis in HalfU.S. Deaths From Cancer Continue to DeclineAlmost All Cancer Patients Respond Well to COVID-19 VaccinesCould Too Many Antibiotics Raise Your Odds for Colon Cancer?Too Little Sunlight, Vitamin D May Raise Colon Cancer RiskShining a Light on SunscreensGap in Breast Cancer Survival for Black, White Patients Shrinks, But Not by EnoughCost a Barrier to Cervical Cancer Screening for Many U.S. WomenMost Americans Don't Follow Diets That Could Prevent Cancer
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Almost All Cancer Patients Respond Well to COVID-19 Vaccines

HealthDay News
by Robert Preidt
Updated: Jul 6th 2021

new article illustration

TUESDAY, July 6, 2021 (HealthDay News) -- Most cancer patients have a good immune response to COVID-19 mRNA vaccines, new research shows.

Two of the three approved vaccines in the United States -- Pfizer and Moderna -- are mRNA vaccines.

Researchers assessed 131 cancer patients and found that 94% developed antibodies to the new coronavirus three to four weeks after their second dose of a mRNA vaccine.

Patients' median age was 63 (meaning half were older, half younger). Most (106) had solid tumors.

Patients with blood cancers such as myeloma and Hodgkin's lymphoma were less likely to respond to vaccination than those with solid tumors.

"We could not find any antibodies against the virus in those patients," said corresponding author Dr. Dimpy Shah of the Mays Cancer Center at the University of Texas at San Antonio. "That has implications for the future. Should we provide a third dose of vaccine after cancer therapy has completed in certain high-risk patients?"

Among high-risk patients, those receiving the drug Rituximab within six months of vaccination developed no antibodies. Rituximab is a monoclonal antibody used to treat blood cancers and autoimmune diseases.

Patients on chemo developed antibody response, but it was weaker than in the general population, according to findings recently published in the journal Cancer Cell.

"How that relates to protection against COVID-19, we don't know yet," Shah said.

The findings suggest that high-risk patients should take precautions against infection even after vaccination, the researchers said.

They also found a significant differences in cancer patients' immune response when they received two vaccine doses compared to one. "At least for patients with cancer, two doses are very important for robust antibody response," Shah said.

Eighty percent of cancer patients studied were white people; 18% were Hispanic patients; and 2% were Black patients.

"We recommend that future studies be done in Black, Asian and Hispanic patients, as well, to see if there are any differences in vaccination immune response," said study senior co-author Dr. Ruben Mesa, executive director of the Mays Cancer Center.

The study did not examine coronavirus variants, including the highly contagious Delta variant, and it did not analyze how infection-fighting T-cells and B-cells in the cancer patients responded to vaccination.

More information

The American Cancer Society has more on COVID-19.


SOURCE: University of Texas Health Science Center at San Antonio, news release, July 1, 2021